Anaheim Bio Raises €40M in Series A Funding

Anaheim Bio, a Leiden, the Netherlands-based preclinical-stage biotechnology company, raised €40M in Series A funding.

Backers included Droia Ventures, Frazier Life Sciences, RTW Investments, Novartis Venture Fund, RV Invest, and Thuja Capital.

The company intends to use the funds to advance ANA-1, a small molecule therapeutic candidate for calcium pyrophosphate deposition disease (CPPD), through IND-enabling studies and into Phase 1.

Led by CEO Ilan Ganot, Anaheim Bio is a preclinical-stage biotechnology company spun out of Alesta Therapeutics.Their platform develops ANA-1, a small molecule inhibitor designed to lower extracellular PPi to directly address the underlying pathology of CPPD by targeting calcium pyrophosphate crystal accumulation.

Don’t just read the news. Own the data. Stop manually tracking deals. Access this round and over 100 others this week—in our structured Master Database (XML) + Weekly Intelligence PDF. 👉 [Access FinSMEs Intelligence Hub]

FinSMEs

05/11/2026